CANY
IGMS

Caxton Associates (New York)’s IGM Biosciences IGMS Stock Holding History

Caxton Associates (New York)’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,009
Closed -$343K – 569
2022
Q2 		$343K Buy
+19,009
New +$339K 0.03% 343

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caxton Associates (New York)'s IGMS Position: Q3 2022 in Review

Caxton Associates (New York) sold out of IGM Biosciences (IGMS) in Q3 2022, closing a stake of 19,009 shares — an estimated $343K sold.

Caxton Associates (New York) first reported a position in IGMS in Q2 2022 and held it in 1 quarter. The position peaked at $343K in Q2 2022. 92 funds tracked by Wall St. Rank hold IGMS as of Q3 2022.

  • Caxton Associates (New York) reported no remaining IGM Biosciences position as of Q3 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 19,009 IGM Biosciences shares in Q3 2022, an estimated $343K.
  • Caxton Associates (New York) first reported a position in IGM Biosciences in Q2 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s IGM Biosciences position peaked at $343K in Q2 2022.
  • 92 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2022.

Based on Caxton Associates (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.